Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for NMSC Prevention in Kidney Transplant Recipients
NCT00129961Phase 4Completed
- Sponsor
- Pfizer
- Start
- Aug 2005
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of sirolimus in non-melanoma skin cancer (NMSC) (2 arms), sponsored by Pfizer. Primary endpoint: New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year at 24 months. Started Aug 2005; status: completed.
02
Drugs
sirolimus
03
Conditions
non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT00129961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129961.